Translating Scientific Advances In Inner Ear Biology Into Novel Therapies For People With Hearing Disorders

Decibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough therapies targeted to specific indications and populations. 

Year Invested: 2015
Location: Cambridge, Mass.

Recent News

August 2, 2018
Decibel Therapeutics Research on The Role of Molecular Diversity in Neurons Critical for Hearing Published in Cell

June 19, 2018
Decibel Therapeutics Closes $55 Million Series C Financing

November 29, 2017
Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus

Read More News

Associated Team Members

Kevin Starr

Craig Muir
Partner/Chief Technology Officer